Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Small-cell lung cancer, drawn from the whole corpus: 402 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Rapid chemoresistance.
Brain metastases.
Background: The blood-brain barrier & brain metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
No screening beyond CT for smokers.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Extensive-stage disease almost always relapses after first-line therapy, so maintenance (lurbinectedin-atezolizumab, tarlatamab) is the current lever; median survival is still barely over a year.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
No validated predictive biomarker for immunotherapy benefit; PD-L1 and TMB do not work in SCLC.
Sequencing of tarlatamab, I-DXd, lurbinectedin, and platinum rechallenge is untested.
Cytokine release syndrome and neurotoxicity of T-cell engagers require inpatient step-up dosing that many community centres cannot provide.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Prophylactic cranial irradiation versus MRI surveillance remains unresolved until SWOG S1827 reads out.
Transformed SCLC arising from EGFR-mutant NSCLC has no dedicated evidence base.
Screening rarely catches SCLC early; prevention is tobacco control.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Trials rarely enrol patients with poor performance status, who are common in this disease.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 69 changes by month →When this page itself was last checked or edited.
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance. (NCCN 1 (durvalumab consolidation, category 1), ESMO-MCBS A)
Low-dose CT screening in heavy smokers finds some SCLC but stage shift is limited; diagnosis by bronchoscopic or CT-guided biopsy; staging with PET/CT and brain MRI. (NCCN SCLC guideline, staging workup)
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.